©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virology. Feb 12, 2015; 4(1): 13-16
Published online Feb 12, 2015. doi: 10.5501/wjv.v4.i1.13
Published online Feb 12, 2015. doi: 10.5501/wjv.v4.i1.13
What psychiatric screening and monitoring might be needed with the new generation of hepatitis C treatments?
Paul J Rowan, University of Texas Health Sciences Center at Houston School of Public Health, Houston, TX 77030, United States
Author contributions: Rowan PJ contributed to this paper.
Correspondence to: Paul J Rowan, PhD, MPH, University of Texas Health Sciences Center at Houston School of Public Health, 1200 Herman Pressler Drive, Houston, TX 77030, United States. paul.j.rowan@uth.tmc.edu
Telephone: +1-713-5009183 Fax: +1-713-5009171
Received: July 29, 2014
Peer-review started: July 29, 2014
First decision: November 3, 2014
Revised: November 11, 2014
Accepted: November 17, 2014
Article in press: November 19, 2014
Published online: February 12, 2015
Processing time: 175 Days and 11.5 Hours
Peer-review started: July 29, 2014
First decision: November 3, 2014
Revised: November 11, 2014
Accepted: November 17, 2014
Article in press: November 19, 2014
Published online: February 12, 2015
Processing time: 175 Days and 11.5 Hours
Core Tip
Core tip: Emerging hepatitis C treatment regimens, which include newer medications such as boceprevir, telaprevir, sofosbuvir, and simeprevir, hold promise to reduce the need for psychosocial screening and monitoring. Thus far, these medications do not seem to have the same psychiatric side effect profile as interferon-alpha.